{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T19:57:21Z","timestamp":1720123041360},"reference-count":12,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2016,3,7]],"date-time":"2016-03-07T00:00:00Z","timestamp":1457308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Crigler\u2010Najjar syndrome (CN) type II is a congenital disease with unconjugated hyperbilirubinemia due to a deficiency of uridine 5\u2032\u2010diphospho\u2010glucuronosyltransferase 1A1. Since the currently proposed treatment with phenobarbital is associated with adverse reactions, we investigated the effect of hypericum extract.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Repetitive determination of total serum bilirubin in a female with CN type II before, during and after daily treatment with 900\u00a0mg hypericum extract on two occasions for 8\u00a0weeks. Confirmation of the enzyme\u2010inducing effect of hypericum using the cytochrome P450 3A4 probe drug i.v. midazolam.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Hypericum reduced midazolam exposure by 42% and the total serum bilirubin concentration by 30 to 35%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Hypericum extract is a potential alternative to phenobarbital in patients with CN type II.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.12869","type":"journal-article","created":{"date-parts":[[2015,12,22]],"date-time":"2015-12-22T01:48:44Z","timestamp":1450748924000},"page":"1002-1004","source":"Crossref","is-referenced-by-count":6,"title":["Reduction of hyperbilirubinemia with hypericum extract (St. John's Wort) in a patient with Crigler\u2010Najjar syndrome type II"],"prefix":"10.1111","volume":"81","author":[{"given":"Oliver","family":"Kummer","sequence":"first","affiliation":[{"name":"Division of Clinical Pharmacology &amp; Toxicology, University Hospital Basel and Department of Biomedicine University of Basel  Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Hammann","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology &amp; Toxicology, University Hospital Basel and Department of Biomedicine University of Basel  Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Haschke","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology &amp; Toxicology, University Hospital Basel and Department of Biomedicine University of Basel  Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Kr\u00e4henb\u00fchl","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology &amp; Toxicology, University Hospital Basel and Department of Biomedicine University of Basel  Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,3,7]]},"reference":[{"key":"e_1_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0098-2997(87)90009-4"},{"key":"e_1_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03600-X"},{"key":"e_1_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342150-00003"},{"key":"e_1_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.130155097"},{"key":"e_1_2_3_6_1","first-page":"83","article-title":"Crigler\u2010Najjar syndrome type II in a 17\u2010year\u2010old girl","volume":"31","author":"Schwegler U","year":"1993","journal-title":"Z Gastroenterol"},{"key":"e_1_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1203\/PDR.0b013e3181598cc5"},{"key":"e_1_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.2987"},{"key":"e_1_2_3_9_1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0009-9236(01)17221-8","article-title":"The effects of St John's wort (\n                     Hypericum perforatum\n                  ) on human cytochrome P450 activity","volume":"70","author":"Wang Z","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_2_3_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0b013e3181ffe8d0"},{"key":"e_1_2_3_11_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2003.10"},{"key":"e_1_2_3_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.1091"},{"key":"e_1_2_3_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/GCO.0000000000000052"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.12869","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.12869","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T16:10:02Z","timestamp":1696349402000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.12869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,7]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.1111\/bcp.12869"],"URL":"https:\/\/doi.org\/10.1111\/bcp.12869","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,7]]}}}